Literature DB >> 27006202

A highly sensitive assay for xanthine oxidoreductase activity using a combination of [(13) C2 ,(15) N2 ]xanthine and liquid chromatography/triple quadrupole mass spectrometry.

Takayo Murase1, Mitsuru Oka2, Mai Nampei3, Atsushi Miyachi1, Takashi Nakamura3.   

Abstract

In this study, we developed a highly sensitive assay for xanthine oxidoreductase (XOR) activity utilizing a combination of [(13) C2 ,(15) N2 ]xanthine and liquid chromatography (LC)/triple quadrupole mass spectrometry (TQMS). In this assay, the amount of [(13) C2 ,(15) N2 ]uric acid (UA) produced by XOR was determined by using LC/TQMS. For this assay, we synthesized [(13) C2 ,(15) N2 ]xanthine as a substrate, [(13) C2 ,(15) N2 ]UA as an analytical standard, and [(13) C3 ,(15) N3 ]UA as an internal standard. The [(13) C2 ,(15) N2 ]UA calibration curve obtained using LC/TQMS under the selected reaction monitoring mode was evaluated, and the results indicated good linearity (R(2)  = 0.998, weighting of 1/x(2) ) in the range of 20 to 4000 nM. As a model reaction of less active samples, the XOR activity of serial-diluted mouse plasma was measured. Thereby, the XOR activity of the 1024-fold-diluted mouse plasma was 4.49 ± 0.44 pmol/100 μL/h (mean ± standard deviation, n = 3). This value is comparable to the predicted XOR activity value of healthy human plasma. Hence, this combination method may be used to obtain high-sensitivity measurements required for XOR activity analysis on various organs or human plasma.
Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  LC/TQMS; stable isotope-labeled substrate; uric acid; xanthine; xanthine oxidoreductase activity

Mesh:

Substances:

Year:  2016        PMID: 27006202     DOI: 10.1002/jlcr.3390

Source DB:  PubMed          Journal:  J Labelled Comp Radiopharm        ISSN: 0362-4803            Impact factor:   1.921


  10 in total

Review 1.  Roles of selected non-P450 human oxidoreductase enzymes in protective and toxic effects of chemicals: review and compilation of reactions.

Authors:  Slobodan P Rendić; Rachel D Crouch; F Peter Guengerich
Journal:  Arch Toxicol       Date:  2022-06-01       Impact factor: 6.168

2.  Possible role of insulin resistance in activation of plasma xanthine oxidoreductase in health check-up examinees.

Authors:  Masafumi Kurajoh; Shinya Fukumoto; Seigo Akari; Takayo Murase; Takashi Nakamura; Kanae Takahashi; Hisako Yoshida; Shinya Nakatani; Akihiro Tsuda; Tomoaki Morioka; Katsuhito Mori; Yasuo Imanishi; Kazuto Hirata; Masanori Emoto
Journal:  Sci Rep       Date:  2022-06-18       Impact factor: 4.996

3.  Xanthine oxidoreductase activity is correlated with hepatic steatosis.

Authors:  Chisako Yagi; Yoshiki Kusunoki; Taku Tsunoda; Takayo Murase; Takashi Nakamura; Keiko Osugi; Mana Ohigashi; Akiko Morimoto; Akio Miyoshi; Miki Kakutani-Hatayama; Kae Kosaka-Hamamoto; Manabu Kadoya; Kosuke Konishi; Takuhito Shoji; Hidenori Koyama
Journal:  Sci Rep       Date:  2022-07-19       Impact factor: 4.996

4.  Relationship between plasma xanthine oxidoreductase activity and left ventricular ejection fraction and hypertrophy among cardiac patients.

Authors:  Yuki Fujimura; Yohei Yamauchi; Takayo Murase; Takashi Nakamura; Shu-Ichi Fujita; Tomohiro Fujisaka; Takahide Ito; Koichi Sohmiya; Masaaki Hoshiga; Nobukazu Ishizaka
Journal:  PLoS One       Date:  2017-08-10       Impact factor: 3.240

5.  Xanthine oxidoreductase activity is associated with serum uric acid and glycemic control in hemodialysis patients.

Authors:  Ayumi Nakatani; Shinya Nakatani; Eiji Ishimura; Takayo Murase; Takashi Nakamura; Mari Sakura; Yu Tateishi; Akihiro Tsuda; Masafumi Kurajoh; Katsuhito Mori; Masanori Emoto; Masaaki Inaba
Journal:  Sci Rep       Date:  2017-11-13       Impact factor: 4.379

6.  Plasma xanthine oxidoreductase activity in patients with decompensated acute heart failure requiring intensive care.

Authors:  Hirotake Okazaki; Akihiro Shirakabe; Masato Matsushita; Yusaku Shibata; Tomofumi Sawatani; Saori Uchiyama; Kennichi Tani; Takayo Murase; Takashi Nakamura; Tsutomu Takayasu; Miwako Asano; Nobuaki Kobayashi; Noritake Hata; Kuniya Asai; Wataru Shimizu
Journal:  ESC Heart Fail       Date:  2019-01-08

7.  Metabolomics analysis elucidates unique influences on purine / pyrimidine metabolism by xanthine oxidoreductase inhibitors in a rat model of renal ischemia-reperfusion injury.

Authors:  Takashi Tani; Ken Okamoto; Megumi Fujiwara; Akira Katayama; Shuichi Tsuruoka
Journal:  Mol Med       Date:  2019-08-22       Impact factor: 6.354

8.  Plasma Xanthine Oxidoreductase Activity Is Associated with a High Risk of Cardiovascular Disease in a General Japanese Population.

Authors:  Yuka Kotozaki; Mamoru Satoh; Kozo Tanno; Hideki Ohmomo; Ryo Otomo; Fumitaka Tanaka; Takahito Nasu; Satoru Taguchi; Hiroto Kikuchi; Takamasa Kobayashi; Atsushi Shimizu; Kiyomi Sakata; Jiro Hitomi; Kenji Sobue; Makoto Sasaki
Journal:  Int J Environ Res Public Health       Date:  2021-02-16       Impact factor: 3.390

9.  Association of plasma xanthine oxidoreductase activity with blood pressure affected by oxidative stress level: MedCity21 health examination registry.

Authors:  Shio Yoshida; Masafumi Kurajoh; Shinya Fukumoto; Takayo Murase; Takashi Nakamura; Hisako Yoshida; Kazuto Hirata; Masaaki Inaba; Masanori Emoto
Journal:  Sci Rep       Date:  2020-03-10       Impact factor: 4.379

10.  Insulin Resistance Associated with Plasma Xanthine Oxidoreductase Activity Independent of Visceral Adiposity and Adiponectin Level: MedCity21 Health Examination Registry.

Authors:  Masafumi Kurajoh; Shinya Fukumoto; Takayo Murase; Takashi Nakamura; Takuma Ishihara; Hirofumi Go; Kouji Yamamoto; Shinya Nakatani; Akihiro Tsuda; Tomoaki Morioka; Katsuhito Mori; Yasuo Imanishi; Masaaki Inaba; Masanori Emoto
Journal:  Int J Endocrinol       Date:  2019-12-30       Impact factor: 3.257

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.